[CAS NO. 496775-62-3] EltrombopagOlamine

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [496775-62-3]

Catalog

HY-15306A

Brand

MCE

CAS

496775-62-3

DESCRIPTION [496775-62-3]

Overview

MDL	MFCD22380664
Molecular Weight	564.63
Molecular Formula	C29H36N6O6
SMILES	O=C(C1=CC(C2=CC=CC(N/N=C3C(C)=NN(C4=CC=C(C)C(C)=C4)C/3=O)=C2O)=CC=C1)O.NCCO.NCCO

For research use only. We do not sell to patients.

8 Publications Citing Use of MCE

Summary

Eltrombopag Olamine (Eltrombopag diethanolamine salt) is an orally active thrombopoietin receptor nonpeptide agonist. Eltrombopag Olamine owns thrombopoietic activity, and has been used to research low blood platelet counts with chronic immune thrombocytopenia. Eltrombopag Olamine can be used for the research of cardiovascular. Eltrombopag Olamine also has highly inhibitory effects against multidrug resistant Staphylococcus aureus . Eltrombopag Olamine can induce apoptosis in hepatocellular carcinomab (HCC) as well ^[1] ^[2] ^[3] ^[4] ^[5] .

IC50 & Target

Thrombopoietin Receptor, Staphylococcus aureus , Apoptosis ^[1] ^[3] ^[5]

In Vitro

Eltrombopag (0.002-50 μM; 4 h) possesses activity in murine BAF3 cells transfected with the luciferase reporter gene ^[1] .
Eltrombopag (30 μM; 120 min) affects the activates of p-STAT5 in N2C-Tpo cells ^[1] .
Eltrombopag (30 μM; 120 min) activates p-STAT5 in megakaryocytes ^[1] .
Eltrombopag (0.1 nM-10 μM; 30 min) stimulates proliferation of BAF3/hTpoR cells ^[1] .
Eltrombopag (0.03-3 μM; 10 days) increases the differentiation of bone marrow CD34 ⁺ cells into CD41 ⁺ megakaryocytes ^[1] .
Eltrombopag (0-3 μM; 72 h) affects N2C-Tpo cell apoptosis ^[1] .
Eltrombopag efficiently inhibits Pneumococcal growth with MIC ₅₀ of 0.3 mg/L, but shows no activity against Gram-negative bacteria ^[3] .
Eltrombopag (0-200 mg/L; 24 h; Caco-2 and HepG2 cells) inhibits Staphylococcus aureus growth with an MIC ₅₀ of 1.5 mg/L, and exhibits higher potency when co-treats with Vancomycin (HY-B0671) with an MIC ₅₀ of 1.2 mg/L ^[3] .
Eltrombopag (0 or 10 μg/mL; 72 h) significantly induces G0/G1 phase arrest in Huh7 cells ^[5] .
Eltrombopag (0.1-100 μg/mL; 72 h) exhibits anti-proliferative activity against HCC cell lines ^[5] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay ^[1]

Cell Line:	Murine BAF3 cells
Concentration:	0.002-50 μM
Incubation Time:	4 hours
Result:	Effectively inhibited murine BAF3 cells with human TpoR with an EC ₅₀ value of 0.27 μM.

Western Blot Analysis ^[1]

Cell Line:	N2C-Tpo cells and CD34 ⁺
Concentration:	30 μM for N2C-Tpo cells; 0, 1, 3 and 10 μM for CD34 ⁺
Incubation Time:	120 min for N2C-Tpo cells; 30 min for CD34 ⁺
Result:	Activated phospho-STAT5 and maximum signal intensity exhibited at 60 minutes after treatment in N2C-Tpo cells. Dose-dependently activated STAT5 phosphorylation at 30 minutes after treatment in CD34 ⁺ .

Cell Proliferation Assay ^[1]

Cell Line:	BAF3/hTpoR cells
Concentration:	0.1 nM-10 μM
Incubation Time:	2 days
Result:	Promoted BAF3/hTpoR cells proliferation after incubated for 2 days with an EC 50 of 0.03 μM.

Cell Differentiation Assay ^[1]

Cell Line:	CD34 ⁺
Concentration:	0.003, 0.01, 0.03, 0.1, 0.3, 1 and 3 μM
Incubation Time:	10 days
Result:	Dose-dependently stimulated the differentiation from bone marrow CD34 ⁺ cells to CD41 ⁺ megakaryocytes with an EC 50 value of 0.1 μM.

Apoptosis Analysis ^[1]

Cell Line:	N2C-Tpo cells
Concentration:	0, 0.003, 0.01, 0.03, 0.1, 0.3, 1 and 3 μM
Incubation Time:	72 hours
Result:	Exhibited dose-dependently antiapoptotic effects N2C-Tpo cells with a concentration over 0.03 μM.

Cell Proliferation Assay ^[5]

Cell Line:	Huh7, HepG2 and Hep3B cells (preloaded with iron (500 μg/ml FAC) for 24 h)
Concentration:	0.1-100 μg/mL
Incubation Time:	72 h
Result:	Exhibited anti-proliferative activity against HCC cell lines with IC ₅₀ s of 5.7 μg/ml for Huh7, 5.4 μg/ml for HepG2, and 4.7 μg/ml for Hep3B.

Cell Cycle Analysis ^[5]

Cell Line:	Huh7 cells
Concentration:	0 or 10 μg/mL
Incubation Time:	72 h
Result:	Significantly induced G0/G1 phase arrest.

In Vivo

Eltrombopag Olamine (10 mg/kg; p.o. once a day for 5 days) shows good tolerance in chimpanzees ^[1] .
Eltrombopag Olamine (17.6 mg/kg; IP; once a day for 2 days) significantly reduces mean S. aureus counts in mice nasal infection ^[3] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female chimpanzees ^[1]
Dosage:	10 mg/kg
Administration:	Oral gavage; 10 mg/kg once a day; for 5 days
Result:	Appeared a goes up and then goes back tendency of platelet counts after treatment, and showed no bad effects of hematology, coagulation, or clinical chemistry parameters on animal.

Animal Model:	C57BL/6 male mice (7 weeks, 20-22 g; injected S. aureus (5 × 10 ⁸ CFU suspended in 40 µL PBS) into the nasal cavities) ^[3]
Dosage:	17.6 mg/kg
Administration:	IP; once a day for 2 days
Result:	Significantly reduced mean bacterial counts (5.0 × 10 ⁶ CFU/lung) in the nasal infection model compared with control PBS (5.2 × 10 ⁷ CFU/lung) mice.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT01821625	University of Texas Southwestern Medical Center\|GlaxoSmithKline	Thrombocytopenia\|Hepatitis C	April 2013	Phase 2\|Phase 3
NCT03718533	Novartis Pharmaceuticals\|Novartis	Poor Graft Function	December 17, 2018	Phase 2
NCT00442871	GlaxoSmithKline	Purpura, Thrombocytopaenic, Idiopathic	September 28, 2006	Phase 1
NCT01893372	M.D. Anderson Cancer Center\|GlaxoSmithKline\|Novartis	Leukemia	October 2013	Phase 2
NCT00424177	GlaxoSmithKline	Purpura, Thrombocytopaenic, Idiopathic	March 2007	Phase 2
NCT01481220	Nordic MDS Group\|GlaxoSmithKline	Myelodysplastic Syndrome\|Thrombocytopenia	October 2011	Phase 1
NCT03701217	Nanfang Hospital of Southern Medical University\|Second Affiliated Hospital, Sun Yat-Sen University\|Guangzhou First People´s Hospital\|Southern Medical University, China\|Wuhan General Hospital of Guangzhou Military Command\|Third Affiliated Hospital, Sun Yat-Sen University\|Dongguan Kanghua Hospital	Eltrombopag\|Thrombocytopenia\|Acute Myeloid Leukemia	September 10, 2018	Phase 2\|Phase 3
NCT00102726	GlaxoSmithKline	Thrombocytopaenia	February 2005	Phase 2
NCT00888901	Ingrid Pabinger, MD\|GlaxoSmithKline\|Medical University of Vienna	Idiopathic Thrombocytopenic Purpura	May 2009	Phase 4
NCT04600960	Institute of Hematology & Blood Diseases Hospital\|Tianjin Medical University Cancer Institute and Hospital\|Tianjin Medical University Second Hospital\|Tianjin Third Central Hospital\|Tianjin People´s Hospital\|Henan Cancer Hospital\|The Second Affiliated Hospital of Kunming Medical University	Chemotherapy-induced Thrombocytopenia\|Eltrombopag	December 31, 2020	Phase 2
NCT02254434	GlaxoSmithKline	Cirrhosis, Liver	August 28, 2014	Phase 1
NCT04485416	Anjali Pawar\|University of California, Davis	Solid Tumor, Childhood\|Solid Tumor	July 16, 2021	Phase 1
NCT01715779	Novartis	Hepatitis C	August 2012
NCT01000051	M.D. Anderson Cancer Center\|Novartis Pharmaceuticals	Thrombocytopenia	February 17, 2010	Phase 2
NCT03988608	Novartis Pharmaceuticals\|Novartis	Aplastic Anemia	December 9, 2019	Phase 2
NCT02158936	Novartis Pharmaceuticals\|Novartis	Thrombocytopaenia	June 10, 2014	Phase 3
NCT01235988	GlaxoSmithKline	Thrombocytopaenia	August 2009
NCT02446145	Technische Universität Dresden\|Novartis	Acute Myeloid Leukemia	May 2015	Phase 2
NCT01791101	Gruppo Italiano Malattie EMatologiche dell´Adulto	Thrombocytopenia	September 16, 2013	Phase 2
NCT04917679	Qilu Hospital of Shandong University	Thrombocytopenia	September 1, 2020	Phase 2
NCT01491594	Duke University\|GlaxoSmithKline	Sarcoma, Soft Tissue\|Osteosarcoma\|Neoplasms, Connective and Soft Tissue	April 2012	Phase 1
NCT01133860	IRCCS Policlinico S. Matteo\|University of Pavia\|GlaxoSmithKline\|Azienda Ospedaliera di Padova\|Azienda Ospedaliera di Perugia\|Fondazione Telethon	Blood Platelet Disorders	January 2009	Phase 2
NCT01439321	GlaxoSmithKline	Immune Thrombocytopenic Purpura	November 2010
NCT05286164	Tel-Aviv Sourasky Medical Center\|Novartis	CART Treatment\|B Cell Lymphoma	April 2022	Phase 2
NCT04797000	Novartis Pharmaceuticals\|Novartis	Myelodysplastic Syndromes	May 25, 2021	Phase 2
NCT00359463	GlaxoSmithKline	Purpura, Thrombocytopaenic, Idiopathic	April 18, 2006	Phase 1
NCT01194167	University of Cincinnati\|GlaxoSmithKline	Thrombocytopenia	August 2010	Phase 2
NCT00102739	GlaxoSmithKline	Purpura, Thrombocytopaenic, Idiopathic	February 2005	Phase 2
NCT01113502	Abramson Cancer Center of the University of Pennsylvania	Acute Myelogenous Leukemia (AML)	June 2010	Phase 1\|Phase 2
NCT02422394	IRCCS Policlinico S. Matteo	Inherited Platelet Disorder	April 2015	Phase 2
NCT01757145	Rabin Medical Center	Hematological Malignancy\|Bone Marrow Failure Syndrome	January 2013	Phase 2
NCT01657552	GlaxoSmithKline	Thrombocytopaenia	August 1, 2012	Phase 1
NCT01772420	Albert Einstein College of Medicine\|National Cancer Institute (NCI)	Adult Myelodysplastic Syndrome\|Anemia\|Chronic Myelomonocytic Leukemia	October 2012	Phase 2
NCT03206086	National Heart, Lung, and Blood Institute (NHLBI)\|National Institutes of Health Clinical Center (CC)	Fanconi Anemia	November 2, 2018	Phase 2
NCT01520909	GlaxoSmithKline	Idiopathic Thrombocytopenic Purpura	March 2012	Phase 3
NCT02071901	Case Comprehensive Cancer Center	Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome\|Adult Acute Basophilic Leukemia\|Adult Acute Eosinophilic Leukemia\|Adult Acute Megakaryoblastic Leukemia (M7)\|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)\|Adult Acute Monoblastic Leukemia (M5a)\|Adult Acute Monocytic Leukemia (M5b)\|Adult Acute Myeloblastic Leukemia With Maturation (M2)\|Adult Acute Myeloblastic Leukemia Without Maturation (M1)\|Adult Acute Myeloid Leukemia in Remission\|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Del(5q)\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Adult Acute Myelomonocytic Leukemia (M4)\|Adult Erythroleukemia (M6a)\|Adult Pure Erythroid Leukemia (M6b)\|Secondary Acute Myeloid Leukemia	August 14, 2014	Phase 2
NCT01652599	Hospital Universitario Dr. Jose E. Gonzalez	Immune Thrombocytopenic Purpura	June 2012	Phase 2
NCT01416311	Novartis Pharmaceuticals\|Novartis	Purpura, Thrombocytopaenic, Idiopathic	December 21, 2010
NCT01168921	M.D. Anderson Cancer Center\|GlaxoSmithKline	CLL\|Leukemia	November 3, 2010	Phase 2
NCT01890746	Novartis Pharmaceuticals\|Novartis	Acute Leukaemia	September 5, 2013	Phase 2
NCT04516837	Peking University People´s Hospital	Immune Thrombocytopenia	August 31, 2020	Phase 2
NCT03524612	Novartis Pharmaceuticals\|Novartis	Immune Thrombocytopenic Purpura (ITP)	November 2, 2018	Phase 2
NCT03025698	Novartis Pharmaceuticals\|Novartis	Aplastic Anemia	September 30, 2017	Phase 2
NCT00903929	Jane Liesveld\|University of Rochester	Thrombocytopenia\|Acute Radiation Syndrome	December 2009	Phase 1
NCT04346654	Novartis Pharmaceuticals\|Novartis	Immune Thrombocytopenia (ITP)	October 9, 2020	Phase 2
NCT03664518	Institute of Hematology & Blood Diseases Hospital\|Novartis\|Qilu Hospital of Shandong University\|The Second Affiliated Hospital of Kunming Medical University\|Tianjin First Central Hospital\|Tianjin Medical University Second Hospital\|Henan Cancer Hospital\|The Second Hospital of Hebei Medical University\|North China University of Technology Affiliated Hospital\|The Affiliated Hospital of Qingdao University\|The First Affiliated Hospital of University of Science and Technology of China\|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School\|Second Affiliated Hospital of Guangzhou Medical University	Thrombocytopenia Purpura\|Chronic HBV Infection	December 4, 2018	Phase 2
NCT01610180	Fondazione Progetto Ematologia	Purpura, Thrombocytopenic, Idiopathic\|Autoimmune Thrombocytopenic Purpura\|Autoimmune Thrombocytopenia\|Chronic Lymphocytic Leukemia\|Non Hodgkin´s Lymphoma	June 2012	Phase 2
NCT03754634	Shandong University\|The Affiliated Hospital of the Chinese Academy of Military Medical Sciences\|Anhui Medical University\|The First Affiliated Hospital of Dalian Medical University\|Shenzhen Second People´s Hospital\|Zhejiang Provincial Hospital of TCM	Thrombocytopenia	May 1, 2019	Phase 2
NCT00516321	GlaxoSmithKline	Hepatitis C, Chronic	October 2007	Phase 3
NCT03437603	The First Affiliated Hospital of Soochow University	Poor Graft Function	February 2018	Phase 2
NCT00903422	GlaxoSmithKline	Myelodysplastic Syndrome	May 14, 2009	Phase 1
NCT03902041	Shandong Provincial Hospital	Allogeneic Hematopoietic Stem Cell Transplantation\|Eltrombopag	May 1, 2019
NCT01621204	McMaster University\|GlaxoSmithKline\|Hamilton Health Sciences Corporation\|Novartis	Immune Thrombocytopenic Purpura	October 2012	Phase 3
NCT02010645	M.D. Anderson Cancer Center\|GlaxoSmithKline	Leukemia	March 2014	Phase 2
NCT01762761	Novartis Pharmaceuticals\|Novartis	Purpura, Thrombocytopenic, Idiopathic and Hepatitis C	February 18, 2013	Phase 3
NCT01328587	National Heart, Lung, and Blood Institute (NHLBI)\|National Institutes of Health Clinical Center (CC)	Moderate Aplastic Anemia\|Unilineage Bone Marrow Failure Disorders	April 1, 2011	Phase 2
NCT02998645	Novartis Pharmaceuticals\|Novartis	Severe Aplastic Anemia	May 11, 2017	Phase 2
NCT01286675	Dana-Farber Cancer Institute	Multiple Myeloma	March 2011	Early Phase 1
NCT00828750	GlaxoSmithKline	Idiopathic Thrombocytopenic Purpura\|Purpura, Thrombocytopenic, Idiopathic	May 2008	Phase 3
NCT02201290	Novartis Pharmaceuticals\|Novartis	Purpura, Thrombocytopenic, Idiopathic	June 18, 2013	Phase 3
NCT02773225	B. Höchsmann\|University of Ulm	Anemia, Aplastic	January 27, 2015	Phase 2\|Phase 3
NCT01891994	National Heart, Lung, and Blood Institute (NHLBI)\|National Institutes of Health Clinical Center (CC)	Severe Aplastic Anemia (SAA)	June 28, 2013	Phase 2
NCT01064336	GlaxoSmithKline	Purpura, Thrombocytopaenic, Idiopathic	March 2010
NCT01703169	University of Utah\|Novartis	Severe Aplastic Anemia\|Very Severe Aplastic Anemia\|Moderate Aplastic Anemia	November 2012	Phase 2
NCT04328727	Novartis Pharmaceuticals\|Novartis	Severe Aplastic Anemia (SAA)	November 4, 2020	Phase 2
NCT00996216	GlaxoSmithKline	Hepatitis C	September 2009	Phase 3
NCT03413306	Federal Research Institute of Pediatric Hematology, Oncology and Immunology	Acquired Aplastic Anemia	December 10, 2016	Phase 3
NCT00922883	National Heart, Lung, and Blood Institute (NHLBI)\|National Institutes of Health Clinical Center (CC)	Anemia, Aplastic\|Anemia, Hypoplastic\|Thrombocytopenia	May 29, 2009	Phase 2
NCT00833378	GlaxoSmithKline	Hepatitis C	January 19, 2009	Phase 1
NCT01428635	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive\|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive\|Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive\|Primary Myelofibrosis\|Thrombocytopenia	January 13, 2012	Phase 2\|Phase 3
NCT02099747	European Society for Blood and Marrow Transplantation\|Novartis\|Pfizer	Severe Aplastic Anemia	July 2015	Phase 3
NCT03638817	University Hospital, Toulouse\|French network for inherited hemorragic diseases\|National Reference Centre for Platelet Pathologies	Thrombocytopenia	August 2, 2019	Phase 2
NCT00643929	GlaxoSmithKline	Purpura, Thrombocytopaenic, Idiopathic	February 2007
NCT03243656	Assiut University	Eltrombopag	December 20, 2017	Phase 4
NCT01927731	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Bone Marrow Transplantation Recipient\|Cord Blood Transplant Recipient\|Hematopoietic Cell Transplantation Recipient	October 14, 2013	Phase 2
NCT05438875	Peking University People´s Hospital\|Beijing Friendship Hospital\|Beijing Tongren Hospital\|Beijing Hospital\|Navy General Hospital, Beijing	Purpura, Thrombocytopenic, Idiopathic	June 24, 2022	Phase 2
NCT04269889	National Heart, Lung, and Blood Institute (NHLBI)\|National Institutes of Health Clinical Center (CC)	Anemia, Diamond-Blackfan	December 1, 2020	Phase 1\|Phase 2
NCT01397149	University of Ulm\|GlaxoSmithKline\|German CLL Study Group\|WiSP Wissenschaftlicher Service Pharma GmbH	Chronic Lymphocytic Leukemia\|Thrombocytopenia	October 2011	Phase 1\|Phase 2
NCT02298075	Gruppo Italiano Malattie EMatologiche dell´Adulto	Immune Thrombocytopenia	April 2016
NCT00688272	GlaxoSmithKline	Purpura, Thrombocytopaenic, Idiopathic	June 2, 2008	Phase 1
NCT01147809	GlaxoSmithKline	Thrombocytopaenia	June 2010	Phase 2
NCT04214951	Peking University People´s Hospital	Corticosteroid-resistant or Relapsed ITP	January 1, 2020
NCT05466201	The First Affiliated Hospital of Soochow University	Stem Cell Transplant Complications	October 1, 2022	Phase 2\|Phase 3
NCT00678587	GlaxoSmithKline	Non-alcoholic Steatohepatitis\|Chronic Liver Disease\|HCV\|NASH - Nonalcoholic Steatohepatitis\|HIV Infection\|Thrombocytopenia\|Hepatitis C Virus\|HBV\|Human Immunodeficiency Virus\|Liver Diseases\|Hepatitis B Virus	June 2008	Phase 3
NCT03830749	Humanity & Health Medical Group Limited	Immune Thrombocytopenia	July 1, 2018	Phase 2
NCT01484314	Dana-Farber Cancer Institute	Thrombocytopenia\|Multiple Myeloma	April 2012	Phase 2
NCT03603795	French Innovative Leukemia Organisation\|Novartis Pharmaceuticals	Acute Myeloid Leukemia	October 11, 2018	Phase 2
NCT04102033	Assiut University	Immune Thrombocytopenia	November 1, 2019	Phase 4
NCT04542382	University of California, San Francisco\|Food and Drug Administration (FDA)	Healthy Volunteers	February 1, 2022	Phase 1
NCT05369377	Peking University People´s Hospital\|Beijing Hospital\|Navy General Hospital, Beijing\|Beijing Aerospace General Hospital\|Qilu Hospital of Shandong University\|Beijing Tongren Hospital	Immune Thrombocytopenia	June 1, 2022	Phase 2
NCT02093325	Chang Gung Memorial Hospital\|Novartis	Solid Tumor	March 2014	Phase 3
NCT02834286	Hospital Universitario Dr. Jose E. Gonzalez	Immune Thrombocytopenia	March 2015	Phase 2
NCT03412188	Nayera Hazaa Elsherif\|Ain Shams University	Idiopathic Thrombocytopenic Purpura	August 1, 2018	Not Applicable
NCT02404025	Novartis Pharmaceuticals\|Novartis	Aplastic Anemia	May 12, 2015	Phase 2
NCT01880047	Weill Medical College of Cornell University\|Novartis	Immune Thrombocytopenia\|Platelet Disorder	February 2013	Phase 2
NCT01636778	GlaxoSmithKline	Hepatitis C, Chronic	July 2012	Phase 2
NCT00487968	GlaxoSmithKline	Healthy Subjects\|Purpura, Thrombocytopenic, Idiopathic	May 2007	Phase 1
NCT01440374	Novartis Pharmaceuticals\|Novartis	Thrombocytopaenia	September 2011	Phase 2
NCT01236014	GlaxoSmithKline	Thrombocytopaenia	August 2009
NCT00861601	GlaxoSmithKline	Liver Diseases	January 2009	Phase 2
NCT04837703	Novartis Pharmaceuticals\|Novartis	Thrombocytopenia
NCT03771378	Wuhan Union Hospital, China\|The First Affiliated Hospital of Nanchang University\|The Third Xiangya Hospital of Central South University\|The First People´s Hospital of Yuhang District\|Xiangyang Central Hospital	Primary Immune Thrombocytopenia	January 16, 2019	Phase 4
NCT00358540	GlaxoSmithKline	Thrombocytopaenia	June 1, 2006	Phase 1
NCT01098487	GlaxoSmithKline	Purpura, Thrombocytopaenic, Idiopathic	May 2010	Phase 4
NCT03515096	Shenzhen Second People´s Hospital	Eltrombopag\|Hematopoietic Stem Cell Transplantation\|Thrombocytopenia	July 1, 2018	Phase 3
NCT00902018	Weill Medical College of Cornell University\|GlaxoSmithKline	Immune Thrombocytopenia	January 2009	Phase 2
NCT02281370	GlaxoSmithKline	Purpura, Thrombocytopenic, Idiopathic	November 5, 2014	Phase 1
NCT05583838	Institute of Hematology & Blood Diseases Hospital\|The Second Hospital of Hebei Medical University\|Xijing Hospital\|The Affiliated Hospital of Inner Mongolia Medical University\|The Second Affiliated Hospital of Kunming Medical University\|Second Affiliated Hospital of Guangzhou Medical University\|Shaanxi Provincial People´s Hospital\|Henan Cancer Hospital\|North China University of Science and Technology Affiliated Hospital\|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University\|The Second Affiliated Hospital of Dalian Medical University\|Second Hospital of Shanxi Medical University\|The Second Affiliated Hospital of Harbin Medical University\|Daqing Oil Field Hospital\|Cangzhou Central Hospital\|Yuncheng Central Hospital\|Shenyang Sunshine Pharmaceutical Co., LTD.	Previously Treated Primary Immune Thrombocytopenia	October 2022	Phase 4
NCT00351468	Novartis Pharmaceuticals\|Novartis	Purpura, Thrombocytopaenic, Idiopathic	June 2006	Phase 3
NCT01433978	Eisai Inc.	Idiopathic Thrombocytopenic Purpura	March 26, 2012	Phase 3
NCT03948529	University Hospital, Lille	Leukemia\|Graft Failure	September 5, 2019	Phase 2
NCT00370331	GlaxoSmithKline	Purpura, Thrombocytopaenic, Idiopathic	November 2006	Phase 3
NCT00961064	National Heart, Lung, and Blood Institute (NHLBI)\|National Institutes of Health Clinical Center (CC)	Myelodysplastic Syndromes\|Thrombocytopenia	March 15, 2011	Phase 2
NCT01550185	Roswell Park Cancer Institute\|GlaxoSmithKline	Adult Acute Basophilic Leukemia\|Adult Acute Eosinophilic Leukemia\|Adult Acute Megakaryoblastic Leukemia (M7)\|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)\|Adult Acute Monoblastic Leukemia (M5a)\|Adult Acute Monocytic Leukemia (M5b)\|Adult Acute Myeloblastic Leukemia With Maturation (M2)\|Adult Acute Myeloblastic Leukemia Without Maturation (M1)\|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Del(5q)\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Adult Acute Myelomonocytic Leukemia (M4)\|Adult Erythroleukemia (M6a)\|Adult Pure Erythroid Leukemia (M6b)\|Recurrent Adult Acute Myeloid Leukemia	May 2012	Phase 1
NCT01072162	GlaxoSmithKline	Purpura, Thrombocytopaenic, Idiopathic	January 12, 2010	Phase 1
NCT00908037	GlaxoSmithKline	Purpura, Thrombocytopaenic, Idiopathic	September 30, 2009	Phase 2
NCT01940562	moshe yeshurun\|GlaxoSmithKline\|Rabin Medical Center	Pediatric Patients Undergoing Allogeneic Cord Blood Transplantation.	October 2013	Phase 2
NCT00529568	GlaxoSmithKline	Hepatitis C, Chronic	October 2007	Phase 3
NCT04518878	Peking University People´s Hospital	Immune Thrombocytopenia	August 31, 2020	Phase 1
NCT02323178	Groupe Francophone des Myelodysplasies\|GlaxoSmithKline\|Novartis	CMML\|Thrombocytopenia	August 7, 2014	Phase 1\|Phase 2
NCT05049668	European Society for Blood and Marrow Transplantation	Severe Aplastic Anemia	October 2021
NCT01055600	GlaxoSmithKline	Thrombocytopaenia	March 2013	Phase 4
NCT03844360	Wei Zhao\|Cancer Institute and Hospital, Chinese Academy of Medical Sciences\|Shandong University	Hematological Neoplasms	January 31, 2016	Phase 4
NCT01488565	Peter MacCallum Cancer Centre, Australia\|GlaxoSmithKline\|Celgene Corporation	Myelodysplastic Syndromes (MDS)\|Acute Myeloid Leukaemia (AML)	December 2010	Phase 2
NCT00540423	GlaxoSmithKline	Chronic Idiopathic Thrombocytopenic Purpura\|Purpura, Thrombocytopenic, Idiopathic	September 2007	Phase 3
NCT01286038	H. Lee Moffitt Cancer Center and Research Institute\|GlaxoSmithKline	Myelodysplastic Syndrome (MDS)\|Thrombocytopenia	April 6, 2011	Phase 1
NCT01656252	PrECOG, LLC.\|GlaxoSmithKline\|Novartis	Acute Myeloid Leukemia	July 2012	Phase 1\|Phase 2
NCT03939637	Baylor College of Medicine\|Boston Children´s Hospital\|University of California, San Francisco	Immune Thrombocytopenia	May 2, 2019	Phase 3
NCT01500538	Peter MacCallum Cancer Centre, Australia\|GlaxoSmithKline\|Merck Sharp & Dohme LLC	Follicular Lymphoma\|Marginal Zone Lymphoma\|Mantle Cell Lymphoma	October 2012	Phase 2
NCT02402998	Gruppo Italiano Malattie EMatologiche dell´Adulto	Primacy Immune Thrombocytopenia	February 24, 2016	Phase 2
NCT04518475	Institute of Hematology & Blood Diseases Hospital\|The Second Affiliated Hospital of Kunming Medical University\|Henan Cancer Hospital\|Tianjin Medical University Second Hospital\|The First Affiliated Hospital of Xiamen University\|Nantong University	Primary Immune Thrombocytopenia (ITP)	August 10, 2020	Phase 4
NCT01386723	Weill Medical College of Cornell University\|Novartis	Immune Thrombocytopenia	June 2011
NCT04915482	Institute of Hematology & Blood Diseases Hospital	Immune Thrombocytopenia (ITP)\|Autoantibodies\|Evan Syndrome\|Connective Tissue Diseases	June 6, 2021	Phase 4
NCT04812483	University Children´s Hospital Basel\|Stiftung zur Förderung medizinischer und biologischer Forschung\|Novartis Pharmaceuticals\|University of Erlangen-Nürnberg, Department of Biology	Primary Immune Thrombocytopenia (ITP)	September 1, 2022	Phase 2
NCT04371939	Federal Research Institute of Pediatric Hematology, Oncology and Immunology	Wiskott-Aldrich Syndrome	November 5, 2019	Phase 2
NCT02148133	Novartis Pharmaceuticals\|Novartis	Cytopaenia	July 23, 2014	Phase 2
NCT01458080	GlaxoSmithKline	Hepatitis C	May 2011
NCT04304820	National Heart, Lung, and Blood Institute (NHLBI)\|National Institutes of Health Clinical Center (CC)	Severe Aplastic Anemia	May 7, 2020	Phase 2
NCT02877212	National Institute of Blood and Marrow Transplant (NIBMT), Pakistan\|Novartis	Immune Thrombocytopenic Purpura (ITP)	July 2016	Phase 3
NCT00110799	GlaxoSmithKline	Hepatitis C, Chronic\|Hepatitis C\|Thrombocytopenia	April 2005	Phase 2

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

DMSO : ≥ 50 mg/mL ( 88.55 mM )

* "≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.7711 mL	8.8554 mL	17.7107 mL
5 mM	0.3542 mL	1.7711 mL	3.5421 mL
10 mM	0.1771 mL	0.8855 mL	1.7711 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 1.07 mg/mL (1.90 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: 1.07 mg/mL (1.90 mM); Suspended solution; Need ultrasonic

* All of the co-solvents are available by MCE.

References

Synonyms

[1,1′-Biphenyl]-3-carboxylic acid, 3′-[(2Z)-2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2′-hydroxy-, compd. with 2-aminoethanol (1:2)

[1,1′-Biphenyl]-3-carboxylic acid, 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-, compd. with 2-aminoethanol (1:2)

SB 497115GR

Eltrombopag olamine

Promacta

Eltrombopag diethanolamine salt

Revolade